Christoph Kaiser.

We predicted a 24-month price of 6.0 percent for the primary end point in the group receiving bare-metal stents, however the observed price was only 4.8 percent. The predicted event price among patients receiving drug-eluting stents was 10.5 percent, however the observed rates were 2.6 percent among patients receiving sirolimus-eluting stents and 3.2 percent among those receiving everolimus-eluting stents. An identical decrease in the price of cardiac events over time has been observed in Sweden.26 Factors contributing to the reduced event rates might have included longer encounter in the usage of drug-eluting stents, differences in individual selection, the fact that no paclitaxel-eluting stents were used, technical factors during the stenting method, improvements in perioperative administration, and the recommendation that dual-antiplatelet therapy be utilized for 12 months instead of 6 months.Study Design and Oversight Patients were randomly assigned in a ratio of around 1:1 to the 12-week or 24-week treatment group . Previously untreated individuals were stratified relating to HCV subgenotype and interleukin 28B genotype , a genetic marker associated with treatment outcomes.26 Previously treated individuals were stratified relating to HCV subgenotype and type of earlier treatment failure: null response, partial response, or relapse .